CA2102624A1 - Transmission-blocking vaccine against malaria - Google Patents

Transmission-blocking vaccine against malaria

Info

Publication number
CA2102624A1
CA2102624A1 CA002102624A CA2102624A CA2102624A1 CA 2102624 A1 CA2102624 A1 CA 2102624A1 CA 002102624 A CA002102624 A CA 002102624A CA 2102624 A CA2102624 A CA 2102624A CA 2102624 A1 CA2102624 A1 CA 2102624A1
Authority
CA
Canada
Prior art keywords
present
transmission
against malaria
vaccines
blocking
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002102624A
Other languages
French (fr)
Other versions
CA2102624C (en
Inventor
David C. Kaslow
Philip J. Barr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Novartis Vaccines and Diagnostics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/697,275 external-priority patent/US5217898A/en
Application filed by Individual filed Critical Individual
Publication of CA2102624A1 publication Critical patent/CA2102624A1/en
Application granted granted Critical
Publication of CA2102624C publication Critical patent/CA2102624C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to transmission-blocking vaccines against malaria, vaccines of the present invention containing a recombinant Pfs25 Plasmodium falciparum protein produced by yeast cells, and to yeast cells producing the protein. Mice and monkeys inoculated with the yeast-expressed Pfs25 of the present invention have developed antibodies with transmission-blocking activity. The present invention also relates to methods of preventing or treating malarial infections using the vaccines of the present invention.
CA002102624A 1991-05-08 1992-05-07 Transmission-blocking vaccine against malaria Expired - Lifetime CA2102624C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/697,275 US5217898A (en) 1988-05-02 1991-05-08 Expression of the P. falciparum transmission-blocking antigen in yeast
US697,275 1991-05-08
PCT/US1992/003579 WO1992019758A1 (en) 1991-05-08 1992-05-07 Transmission-blocking vaccine against malaria

Publications (2)

Publication Number Publication Date
CA2102624A1 true CA2102624A1 (en) 1992-11-09
CA2102624C CA2102624C (en) 2006-09-26

Family

ID=37057068

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002102624A Expired - Lifetime CA2102624C (en) 1991-05-08 1992-05-07 Transmission-blocking vaccine against malaria

Country Status (1)

Country Link
CA (1) CA2102624C (en)

Also Published As

Publication number Publication date
CA2102624C (en) 2006-09-26

Similar Documents

Publication Publication Date Title
CA2123612A1 (en) Hybrid protein between cs from plasmodium and h bsag
EP0717636A4 (en) Malaria recombinant poxvirus vaccine
CA2102918A1 (en) Genetic vaccine for immunodeficiency viruses
AU592749B2 (en) Cloning of dna for protozoal antigens
AU1013701A (en) Modified gp100 and uses thereof
CA2168583A1 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
EP0342860A3 (en) Novel protein, sequences containing the gene therefore, vectors, methods of preparation and use
CA2042236A1 (en) Seroreactive epitopes on proteins of human papillomavirus (hpv) 18
EP0584201A4 (en) Transmission-blocking vaccine against malaria
CA2115927A1 (en) Peptides for inducing cytotoxic t-lymphocyte responses to hepatitis b virus
AU5112990A (en) Dna sequences, recombinant dna and processes for producing antigens of plasmodium falciparum
IL90849A0 (en) Synthetic vaccine against p.falciparum malaria
EP0775746A3 (en) Coccidiosis poultry vaccine
IL97013A (en) Immunoreactive protein of an eimeria merozoite surface antigen, dna encodidng it, the production of the protein and its use as a vaccine
CA2102624A1 (en) Transmission-blocking vaccine against malaria
DE3685917D1 (en) PEPTIDE COMPOSITION FOR THE PRODUCTION OF MALARIA VACCINE, AND FOR THE PREPARATION OF DIAGNOSTIC ITEMS FOR THE DETECTION OF MALARIA-LIKE DISEASES.
IL90134A0 (en) Gene for encoding a human malaria vaccine antigen,malarial vaccines and pharmaceutical compositions
WO1997030159A3 (en) Recombinant protein containing a c-terminal fragment of plasmodium msp-1
WO2000025728A3 (en) Chromosome 2 sequence of the human malaria parasite plasmodium falciparum and proteins of said chromosome useful in anti-malarial vaccines and diagnostic reagents
AU2992489A (en) Method for producing recombinant protein derived from the circumsporozoite gene of plasmodium falciparum
WO1997003187A3 (en) Marek's disease virus genes and their use in vaccines for protection against marek's disease
AU1668097A (en) Malaria recombinant poxvirus vaccine
EP0320034A3 (en) New immunologically active synthetic peptides useful for preparing an antimalarial vaccine
AU5718794A (en) Recombinant nucleic acid, polypeptide material coded thereby and transmission blocking vaccine based thereon for controlling the malaria parasite (plasmodium falciparum )
MY104081A (en) Rhoptry membrane antigen of plasmodium falciparum.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry